The investment, valued at more than EUR 100 million, is part of the company’s global growth strategy and will create 100-plus new jobs in the region. The Lukácsháza site already plays a key role in the global pharmaceutical supply chain: In June 2024, the company inaugurated a state-of-the-art production facility for high-quality prefillable glass syringes at the same location.
“To meet growing demand, we are expanding our manufacturing capacities and presence in therapeutic solutions for the treatment of diabetes and obesity. For this purpose, we are investing more than EUR 100 mln in the development of our Hungarian plant,” said Andreas Reisse, CEO of Schott Pharma.
Ready-to-use cartridges are used for storing biologics, specific drugs, insulin, and hormone therapies designed to treat diabetes, obesity and various immunological diseases, the company noted. With the new facility, Schott Pharma will further broaden its portfolio of high value-added products manufactured in Hungary.
“We sincerely thank the Ministry of Foreign Affairs and Trade for supporting both development projects. Lukácsháza is not only a key site for supply security in the region but also makes a significant contribution to Schott Pharma’s global growth strategy,” said Éva Szabó, head of the Lukácsháza site.
The new cartridge plant will be equipped with cutting-edge technology, including an advanced washing line and steam sterilization process, ensuring product sterility while reducing environmental impact. Manufacturing will be fully integrated and automated, requiring minimal manual intervention to meet the highest quality standards. Lukácsháza will become only the second Schott Pharma site worldwide to produce sterile cartridges, after St. Gallen, Switzerland.
Egis Gyógyszergyár Zrt. is expanding its Körmend site with an investment worth more than HUF 14 billion. The project will increase the plant’s capacities and renew its technological infrastructure, strengthening the strategic importance of the production unit.
Egis is financing the investment from its own resources and HUF 3.5 bln in state support. The aim is to expand production, packaging and storage capacities, as well as further modernize technological infrastructure, the company and the Ministry of Foreign Affairs and Trade said at a joint press conference on July 28.
The investment is part of the ongoing development program at the Körmend site under which the pharmaceutical company is modernizing its tablet plant, upgrading the infrastructure required for the production of galenic preparations (non-solid dosage forms such as creams, ointments, gels, suppositories and solutions) and expanding the packaging unit.
“This development not only increases our production capacities but also represents a technological renewal that enables us to operate more efficiently and sustainably,” said Egis Gyógyszergyár CEO Csaba Poroszlai.
“This is the key to competitiveness, which has traditionally characterized Egis alongside an innovative approach. This investment also signals that our Körmend site, the city’s largest employer, will continue to play a strategic role in the future,” he noted. He added that the goal is to use the best available technologies and equipment.
“These not only comply with the strictest international standards but also significantly enhance efficiency, thus increasing the company’s competitiveness and ultimately the performance of the Hungarian economy,” Poroszlai said.
Egis has intensively developed its Körmend site, where investments worth nearly HUF 29 bln have been carried out since 2018.
This article was first published in the Budapest Business Journal print issue of September 19, 2025.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
